Richmond Pharmacology visits Japan to expand business

Posted:
5
January 2005

Originally published in Nikkan Yakugyo and Japan Medicine.

Jörg Täubel, CEO of Richmond Pharmacology (RPL) – a major British CRO – announced that he is aiming to expand business with pharmaceutical companies based in Japan (including companies with foreign capital affiliation). RPL's sales totaled 10 million pounds last fiscal year, and 25% of this comes from companies based in Japan. The company's sales estimate for this fiscal year is 11 million pounds, and the portion of Japanese based companies is expected to stay the same (25%). Mr. Täubel stated that, “(although, there has been no official discussion yet) we would like to eventually build a partnership with Bellsystem24, a Japanese CRO.”RPL is well regarded for its “bridging studies” of Caucasians and Japanese. 80 Japanese volunteers register for the company's clinical trial every month, most of whom are students studying English. RPL has Japanese doctors and nurses attend to the clinical trials for Japanese volunteers in order to eliminate language problems.RPL currently has contracts with 10 companies that are based in Japan (including companies with foreign capital affiliation). Dr. Täubel is planning on holding business meetings with 8 major companies (including current business partners) between Dec 5th and 11th.

Latest news

Upcoming Event

The 41st Annual Scientific Meeting of the Japanese Society of Clinical Pharmacology and Therapeutics (JSCPT)

4 – 5 December 2020
The 41st Annual Scientific meeting focuses on international collaboration in the pursuit of drug discovery and drug development.
View event

Contributing to our community in 2020

December 17, 2020
Richmond Pharmacology has a long-standing tradition of supporting local, national, and international charities and 2020 is no exception.
Read more

Richmond Pharmacology supports Cardior Pharmaceuticals with the pioneering trial of an oligonucleotide-based drug in heart failure patients

December 14, 2020
Richmond Pharmacology is delighted to welcome the positive Phase Ib results of Cardior Pharmaceuticals lead compound CDR132L for heart failure.
Read more

Marking a milestone for gene editing

November 10, 2020
We are pleased to share that Richmond Pharmacology, in partnership with Intellia Therapeutics and the Royal Free Hospital, have treated the first patient in a landmark CRISPR/Cas9 clinical trial of NTLA-2001
Read more